Literature DB >> 27655291

Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.

Fabian Pitoia1, Erika Abelleira2, Graciela Cross2.   

Abstract

The objective of our study was to evaluate the prognostic value of stimulated thyroglobulin levels at the moment of remnant ablation for predicting an initial excellent or a structural incomplete response to treatment according to the risk of recurrence in patients with differentiated thyroid cancer. Patients were divided into two groups according to the preparation mode for remnant ablation (thyroid hormone withdrawal or recombinant human TSH). We included 219 patients followed-up for at least for 24 months after remnant ablation. The primary endpoint was the best response to initial therapy assessed in the first 9-18 months of follow-up. An excellent response was observed in 45.1 % of patients prepared after recombinant human TSH compared to 44.6 % of patients prepared after thyroid hormone withdrawal (P = NS). The cutoff value of thyroglobulin level after recombinant human TSH for predicting an excellent response was 8 ng/ml (n = 51), with a sensitivity of 73.9 %, and a positive predictive value of 61 %. It was similar for patients with low vs. intermediate to high risk of recurrence. This cutoff value for thyroglobulin level after thyroid hormone withdrawal was 22 ng/ml (n = 168), with a sensitivity of 94.7 % and a positive predictive value of 61.7 %. In the thyroid hormone withdrawal group the thyroglobulin cutoff level was 12 ng/ml for low-risk patients compared to 16 ng/ml for those with intermediate to high risk of recurrence (P = 0.003). The cutoff value of the thyroglobulin level for predicting a structural incomplete response to initial treatment was 20 ng/ml after rhTSH, with a negative predictive value of 91.4 %. This level was higher in thyroid hormone withdrawal group, and it was established at 25 ng/ml, with a negative predictive value of 97.7 %. The stimulated Tg level seems to be different depending on the preparation mode (rhTSH or THW) for RA. It has a high NPV to predict the absence of a structural incomplete response and it is also a good predictor of the initial excellent response and the NED status at the end of follow-up.

Entities:  

Keywords:  Differentiated thyroid cancer; Excellent response; Preparation mode; Remnant ablation; Risk of recurrence; Thyroglobulin levels

Mesh:

Substances:

Year:  2016        PMID: 27655291     DOI: 10.1007/s12020-016-1104-5

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  24 in total

1.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.

Authors:  R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha
Journal:  Thyroid       Date:  2010-10-29       Impact factor: 6.568

2.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

3.  Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients.

Authors:  Maria Grazia Castagna; Fabio Maino; Claudia Cipri; Valentina Belardini; Alexandra Theodoropoulou; Gabriele Cevenini; Furio Pacini
Journal:  Eur J Endocrinol       Date:  2011-07-12       Impact factor: 6.664

4.  Stimulated thyroglobulin level at ablation in differentiated thyroid cancer: the impact of treatment preparation modalities and tumor burden.

Authors:  Renaud Ciappuccini; Juliette Hardouin; Natacha Heutte; Dominique Vaur; Elske Quak; Jean-Pierre Rame; David Blanchard; Dominique de Raucourt; Stéphane Bardet
Journal:  Eur J Endocrinol       Date:  2014-05-27       Impact factor: 6.664

5.  Preablation stimulated thyroglobulin is a good predictor of successful ablation in patients with differentiated thyroid cancer.

Authors:  Daniel B Kendler; Fernanda Vaisman; Rossana Corbo; Rosângela Martins; Mario Vaisman
Journal:  Clin Nucl Med       Date:  2012-06       Impact factor: 7.794

6.  Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence.

Authors:  Fabián Pitoia; Fernando Jerkovich; Carolina Urciuoli; Angélica Schmidt; Erika Abelleira; Fernanda Bueno; Graciela Cross; R Michael Tuttle
Journal:  Thyroid       Date:  2015-08-06       Impact factor: 6.568

7.  Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and ¹³¹I activity in patients with thyroid cancer and low risk of recurrence.

Authors:  Pedro Weslley Rosario; Arthur Cezar Malard Xavier; Maria Regina Calsolari
Journal:  Thyroid       Date:  2010-10-18       Impact factor: 6.568

8.  Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?

Authors:  Tihana Ibrahimpasic; Iain J Nixon; Frank L Palmer; Monica M Whitcher; Robert M Tuttle; Ashok Shaha; Snehal G Patel; Jatin P Shah; Ian Ganly
Journal:  Surgery       Date:  2012-12       Impact factor: 3.982

9.  A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns].

Authors:  S A Hundahl; I D Fleming; A M Fremgen; H R Menck
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

10.  Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems.

Authors:  Fabián Pitoia; Fernanda Bueno; Carolina Urciuoli; Erika Abelleira; Graciela Cross; R Michael Tuttle
Journal:  Thyroid       Date:  2013-07-25       Impact factor: 6.568

View more
  5 in total

Review 1.  [Progress in the research of negative feedback effect of thyroglobulin].

Authors:  Fei Chen; Hongjuan Wang; Qiang Li; Zhichao Li; Yuqian Luo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-01-30

2.  Stimulated thyroglobulin values above 5.6 ng/ml before radioactive iodine ablation treatment following levothyroxine withdrawal is associated with a 2.38-fold risk of relapse in Tg-ab negative subjects with differentiated thyroid cancer.

Authors:  U Mousa; A S Yikilmaz; A Nar
Journal:  Clin Transl Oncol       Date:  2017-03-03       Impact factor: 3.405

3.  Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine.

Authors:  Giulliana Nóbrega; Milena Cavalcanti; Verônica Leite; Lúcio Vilar; Simone Cristina Soares Brandão
Journal:  Endocrine       Date:  2022-03-02       Impact factor: 3.925

4.  BRAF V600E Status and Stimulated Thyroglobulin at Ablation Time Increase Prognostic Value of American Thyroid Association Classification Systems for Persistent Disease in Differentiated Thyroid Carcinoma.

Authors:  Andrea Repaci; Valentina Vicennati; Alexandro Paccapelo; Ottavio Cavicchi; Nicola Salituro; Fabio Monari; Dario de Biase; Giovanni Tallini; Annalisa Altimari; Elisa Gruppioni; Michelangelo Fiorentino; Uberto Pagotto
Journal:  Int J Endocrinol       Date:  2019-04-07       Impact factor: 3.257

5.  The Prognostic Role of Postablative Non-Stimulated Thyroglobulin in Differentiated Thyroid Cancer.

Authors:  Szabina Szujo; Laszlo Bajnok; Beata Bodis; Zsuzsanna Nagy; Orsolya Nemes; Karoly Rucz; Emese Mezosi
Journal:  Cancers (Basel)       Date:  2021-01-15       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.